In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance Belapectin was overall well tolerated with no safety signals; incidence of adverse events and serious adverse events were comparable across the three cohorts Additional data to be presented in early 2025NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated...

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) —Trading to continue under ticker symbol “CYTOF” No reverse stock split plannedAltamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common shares from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with Rule 5550(a)(2) of Nasdaq’s Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. The Company’s common shares will be delisted from Nasdaq at the open of trading on December 20, 2024 and...

SALINAS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces the appointment of Philippe Faraut as Chief Financial Officer of the Company, effective immediately. “We are excited to welcome Philippe as our new CFO,” said Mark Ainsworth, CEO of Lowell Farms Inc. “His extensive financial expertise and leadership across diverse industries make him the ideal addition to our team. Philippe’s proven ability to drive growth and innovation positions Lowell for an exciting new chapter as we continue to expand and elevate our presence in the cannabis industry.” Philippe Faraut is a highly accomplished financial executive with a dynamic career spanning multiple...

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 1 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial....

Correction: The shares were bought by MMH Nysteen Invest AS, a company controlled by board member Maria Moræus Hanssen and related parties.Oslo, 20 December 2024: MMH Nysteen Invest AS, a company controlled by board member Maria Moræus Hanssen and related parties has on 20 December bought 2,575 shares in Scatec ASA at an average price per share of NOK 77.1. After the transaction MMH Nysteen Invest AS owns 13,615 shares in Scatec ASA.Attached is the notification of the transaction in accordance with the Market Abuse Regulation Article 19. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading act.Attachment241220 – Notification of trade primary insiders – MMH Nysteen Invest AS

SHENZHEN, China, Dec. 20, 2024 (GLOBE NEWSWIRE) — NIP Group Inc. (NASDAQ: NIPG) (“NIP Group” or the “Company”), a leading digital entertainment company, is breaking new ground with the introduction of its first MOBA game: Re: Aetatis. This highly anticipated cutting-edge sci-fi MOBA mobile game begins open beta testing on December 24, 2024, inviting players to experience the next evolution in competitive gaming. Re: Aetatis marks NIP Group’s bold entry into the dynamic game publishing market and a major milestone for the Company’s evolution from a top esports organization to a global digital entertainment leader. Following the launch of reservations, Re: Aetatis has garnered significant attention and recognition from players and is poised to become a flagship title in NIP Group’s emerging game portfolio. NIP Group is...